Safety and immunogenicity of the SARS-CoV-2 LYB001 RBD-based VLP vaccine (CHO cell) phase 1 in Chinese adults: a randomized, double-blind, positive-parallel-controlled study-Reference-Cited by-同舟云学术

Safety and immunogenicity of the SARS-CoV-2 LYB001 RBD-based VLP vaccine (CHO cell) phase 1 in Chinese adults: a randomized, double-blind, positive-parallel-controlled study

Published:2024-05-02 Issue:1 Volume:23 Page:498-509
ISSN:1476-0584
Container-title:Expert Review of Vaccines
language:en
Short-container-title:Expert Review of Vaccines

Author:

Tang Rong¹,Zeng Ying²³,Zhou Yu²³,Liang Qi⁴,Kang Wei²³,Yang Zhonghua²³,Zheng Xiaoxiang⁵,Zang Xia⁵,Pan Hongxing¹,Jin Jing²³,Zhu Fengcai¹

Affiliation:

1. Institute for Vaccine Clinical Evaluation, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, People’s Republic of China

2. Medicine and Registration, Process Development, Yantai Patronus Biotech Co. Ltd, Yantai, Shandong, People’s Republic of China

3. Medicine and Registration, Process Development, Guangzhou Patronus Biotech Co. Ltd, Guangzhou, Guangdong, People’s Republic of China

4. Institute of Vaccine Clinical Trials, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, People’s Republic of China

5. Epidemic Data Processing Center, Dongtai City Center for Disease Control and Prevention, Dongtai, People’s Republic of China

Funder

Shandong Province

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14760584.2024.2337051

Reference28 articles.

1. Coronavirus resource center at johns Hopkins university. [cited 2023 Mar 10]. Available from: https://github.com/CSSEGISandData/COVID-19

2. Meta-analysis of SARS-CoV-2 reinfection rate in the world;Ma Y;Chin J Dis Control Prev,2023

3. A survey of COVID-19 vaccine acceptance across 23 countries in 2022

4. COVID-19 vaccine tracker and landscape. [cited 2023 Mar 10]. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines

5. COVID-19 vaccine development: milestones, lessons and prospects

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Functionally Designed Nanovaccines against SARS-CoV-2 and Its Variants;Vaccines;2024-07-12